Future Directions in Biomarker-Based Oncology
Experts in oncology discuss future directions in biomarker-driven therapy.
Read More
NRG1 Fusions in Solid Tumors: The CRESTONE Trial
Dr Mark Socinski describes the design and findings of the CRESTONE trial.
Read More
Current and Future Use of MET Inhibitors in NSCLC
Healthcare professionals who manage patients with non–small cell lung cancer comment on their current experience using MET inhibitors as treatment for patients who harbor MET exon 14 skipping mutations and highlight strategies under investigation that will hopefully address current gaps in therapy.
Read More
MET Inhibitors in NSCLC: Mechanisms of Resistance
The rationale for using MET inhibitors as first-line therapy for patients with non–small cell lung cancer who harbor MET exon 14 skipping mutations and considerations for sequencing later lines of therapy based on what is known to date about mechanisms of resistance to MET inhibitors.
Read More
MET Inhibitors in NSCLC: Toxicity Management
Drs Joshua M. Bauml and Benjamin Levy highlight more common adverse events associated with MET inhibitors used to treat MET exon 14 skipping mutations in non–small cell lung cancer and share strategies to help manage patients on therapy.
Read More
MET Inhibitors in NSCLC: Treatment Selection
A comparison between the MET inhibitors available to treat MET exon 14 skipping mutations in non–small cell lung cancer and factors that should be considered when selecting a type 1 or type 2 MET-directed therapy.
Read More
CNS Response to MET Inhibition in NSCLC
The significance of using MET inhibitors to manage patients who have MET exon 14 skipping mutations in non–small cell lung cancer with CNS (central nervous system) involvement.
Read More
Tepotinib for MET Exon 14 Skipping Mutations in NSCLC
Implications for treating patients with non–small cell lung cancer who harbor MET exon 14 skipping mutations with tepotinib, a MET inhibitor, based on data revealed by the VISION trial.
Read More
Capmatinib for MET Exon 14-Mutated NSCLC
Discussion on the FDA approval of capmatinib, a MET inhibitor, as treatment for patients with MET exon 14-mutated non–small cell lung cancer based on data demonstrated by the GEOMETRY mono-1 study.
Read More
Testing to Identify MET Exon 14 Mutations in NSCLC
Recommendations for using next-generations sequencing panels as well as liquid biopsies to help identify MET exon 14 skipping mutations and other oncogenic drivers in patients with non–small cell lung cancer.
Read More
Advances in Targeting MET Exon 14 Skipping Mutations in NSCLC
Drs Joshua M. Bauml and Benjamin Levy react to the development of novel therapies that specifically target MET exon 14 skipping mutations in non–small cell lung cancer.
Read More
MET Exon 14 Skipping Mutations in NSCLC
Drs Joshua M. Bauml and Lyudmila A. Bazhenova describe what is understood regarding the behavior of MET exon 14 skipping mutations in non–small cell lung cancer and remark on their prevalence among specific patient populations.
Read More
WCLC Updates in Small Cell Lung Cancer
Panelists provide first impressions on recent clinical trials in the treatment of small cell lung cancer and comment on the safety and efficacy of study treatments.
Read More
WCLC Updates in Locally Advanced NSCLC
Key opinion leaders provide insights on chemotherapy and radiotherapy in patients with unresectable, locally advanced non–small cell lung cancer (NSCLC).
Read More
WCLC Updates in Neoadjuvant Therapy for NSCLC
Experts in thoracic oncology discuss the role of single-agent immunotherapy as neoadjuvant therapy and comment on the viability of MPR [major pathologic response] as a surrogate endpoint for non–small cell lung cancer (NSCLC).
Read More
WCLC Updates in Immunotherapy for NSCLC
Key opinion leaders discuss recent trial data on the clinical efficacy of immunotherapy for the treatment of non–small cell lung cancer (NSCLC).
Read More
WCLC Updates on the Emergence of ADCs in NSCLC
Panelists provide insight into emerging clinical trial data on antibody-drug conjugates (ADCs) presented at the IASLC 2020 World Conference on Lung Cancer (WCLC).
Read More
WCLC Updates in KRAS and Rare EGFR-Mutated NSCLC
Experts in thoracic oncology review data presented at the IASLC 2020 World Conference on Lung Cancer (WCLC) and discuss safety and efficacy of targeted agents for patients with KRAS- or EGFR-mutated non–small cell lung cancer (NSCLC).
Read More
Optimizing Testing Strategies in Non–Small Cell Lung Cancer
Read More
MET Exon 14 Mutations in Non–Small Cell Lung Cancer
Read More
Rebiopsy at Progression of ALK-Rearranged NSCLC
Read More
Treating ALK-Rearranged Non–Small Cell Lung Cancer
Read More
Trials in ALK-Rearranged Non–Small Cell Lung Cancer
Read More
Trastuzumab Deruxtecan for HER2+ Non–Small Cell Lung Cancer
Read More